Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Background. In 1999, meningococcal serogroup C conjugate (MCC) vaccines were introduced in the United Kingdom for those under 19 years of age. The impact of this intervention on asymptomatic carriage of meningococci was investigated to establish whether serogroup replacement or protection by herd immunity occurred. Methods. Multicenter surveys of carriage were conducted during vaccine introduction and on 2 successive years, resulting in a total of 48,309 samples, from which 8599 meningococci were isolated and characterized by genotyping and phenotyping. Results. A reduction in serogroup C carriage (rate ratio, 0.19) was observed that lasted at least 2 years with no evidence of serogroup replacement. Vaccine efficacy against carriage was 75%, and vaccination had a disproportionate impact on the carriage of sequence type (ST)-11 complex serogroup C meningococci that (rate ratio, 0.06); these meningococci also exhibited high rates of capsule expression. Conclusions. The impact of vaccination with MCC vaccine on the prevalence of carriage of group C meningococci was consistent with herd immunity. The high impact on the carriage of ST-11 complex serogroup C could be attributed to high levels of capsule expression. High vaccine efficacy against disease in young children, who were not protected long-term by the schedule initially used, is attributed to the high vaccine efficacy against carriage in older age groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The reduction in carriage lasted for at least 2 years after vaccine introduction, with no evidence of serogroup replacement (199).”
From Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis (2010) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The staden sequence analysis package
Staden, R. (1996) · Molecular Biotechnology · doi:10.1007/bf02900361 · Cited by 1,263
Multilocus Sequence Typing of Bacteria
Maiden, M. C. J. (2006) · Annual Review of Microbiology · doi:10.1146/annurev.micro.59.030804.121325 · Cited by 915
Self-citationEffectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
Trotter, C. L., Andrews, N. J., Kaczmarski, E. B., Miller, E., & Ramsay, M. E. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16725-1 · Cited by 571 · cited 1×
“This was fortuitous given that the infant schedule used for MCC vaccines in the United Kingdom at the time of vaccine introduction did not confer long term protection [27].”
BackgroundSelf-citationSequence type analysis and recombinational tests (START)
Jolley, K. A., Feil, E. J., Chan, M.-S., & Maiden, M. C. J. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.12.1230 · Cited by 512
Self-citationmlstdbNet – distributed multi-locus sequence typing (MLST) databases
Jolley, K. A., Chan, M.-S., & Maiden, M. C. (2004) · BMC Bioinformatics · doi:10.1186/1471-2105-5-86 · Cited by 501
Self-citationMiller, E., Salisbury, D., & Ramsay, M. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00299-7 · Cited by 482
Dagan, R., Melamed, R., Muallem, M., Piglansky, L., Greenberg, D., Abramson, O., Mendelman, P. M., Bohidar, N., & Yagupsky, P. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/174.6.1271 · Cited by 477
Immunologic Response of Man to Group B Meningococcal Polysaccharide Vaccines
Wyle, F. A., Artenstein, M. S., Brandt, B. L., Tramont, E. C., Kasper, D. L., Altieri, P. L., Berman, S. L., & Lowenthal, J. P. (1972) · Journal of Infectious Diseases · doi:10.1093/infdis/126.5.514 · Cited by 446
The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica
Cartwright, K. A. V., Stuart, J. M., Jones, D. M., & Noah, N. D. (1987) · Epidemiology and Infection · doi:10.1017/s0950268800066449 · Cited by 421
Self-citationMaiden, M. C., & Stuart, J. M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08679-8 · Cited by 418 · cited 4×
“bacteria [13], which, although rarely isolated from carriers, are”
BackgroundInfluentialSelf-citation
Research works printed but not linked: 1
- 12. Jelfs J, Munro R, Ashton F, Rawlinson W, Caugant DA. Global study of variation in a new variant of the ET-37 complex of Neisseria meningitidis. In: Program and abstracts of the 11th International Pathogenic Neisseria Conference. Nice, France: Editions E.D.K., 1998 :5.
Cited by
Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis
Brouwer, M. C., Tunkel, A. R., & van de Beek, D. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00070-09 · Cited by 930
ESCMID guideline: diagnosis and treatment of acute bacterial meningitis
van de Beek, D., Cabellos, C., Dzupova, O., Esposito, S., Klein, M., Kloek, A. T., Leib, S. L., Mourvillier, B., Ostergaard, C., Pagliano, P., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.01.007 · Cited by 919
Impact of Vaccines; Health, Economic and Social Perspectives
Rodrigues, C. M. C., & Plotkin, S. A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01526 · Cited by 737
Meningococcal carriage by age: a systematic review and meta-analysis
Christensen, H., May, M., Bowen, L., Hickman, M., & Trotter, C. L. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70251-6 · Cited by 654
Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines
Pollard, A. J., Perrett, K. P., & Beverley, P. C. (2009) · Nature Reviews Immunology · doi:10.1038/nri2494 · Cited by 485
Neisseria meningitidis: Biology, Microbiology, and Epidemiology
Rouphael, N. G., & Stephens, D. S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-346-2_1 · Cited by 425
Infections of People with Complement Deficiencies and Patients Who Have Undergone Splenectomy
Ram, S., Lewis, L. A., & Rice, P. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00048-09 · Cited by 405
Meningococcal carriage and disease—Population biology and evolution
Caugant, D. A., & Maiden, M. C. J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.061 · Cited by 381
Self-citationMbaeyi, S. A., Bozio, C. H., Duffy, J., Rubin, L. G., Hariri, S., Stephens, D. S., & MacNeil, J. R. (2020) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6909a1 · Cited by 321
Read, R. C., Baxter, D., Chadwick, D. R., Faust, S. N., Finn, A., Gordon, S. B., Heath, P. T., Lewis, D. J. M., Pollard, A. J., Turner, D. P. J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60842-4 · Cited by 280
Self-citationBorrow, R., Alarcón, P., Carlos, J., Caugant, D. A., Christensen, H., Debbag, R., De Wals, P., Echániz-Aviles, G., Findlow, J., Head, C., et al. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1258308 · Cited by 269
Protein carriers of conjugate vaccines: Characteristics, development and clinical trials
Pichichero, M. E. (2013) · Human vaccines & immunotherapeutics · doi:10.4161/hv.26109 · Cited by 261
Daugla, D., Gami, J., Gamougam, K., Naibei, N., Mbainadji, L., Narbé, M., Toralta, J., Kodbesse, B., Ngadoua, C., Coldiron, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61612-8 · Cited by 256
Self-citationAdvances in the Development of Vaccines against Neisseria meningitidis
Tan, L. K. K., Carlone, G. M., & Borrow, R. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0906357 · Cited by 233
Campbell, H., Andrews, N., Borrow, R., Trotter, C., & Miller, E. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00529-09 · Cited by 213
Self-citationImpact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity
Kristiansen, P. A., Diomandé, F., Ba, A. K., Sanou, I., Ouédraogo, A., Ouédraogo, R., Sangaré, L., Kandolo, D., Aké, F., Saga, I. M., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis892 · Cited by 212
Trotter, C. L., & Maiden, M. C. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.48 · Cited by 203
Self-citationPelton, S. I. (2016) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2016.04.012 · Cited by 199
Acevedo, R., Bai, X., Borrow, R., Caugant, D. A., Carlos, J., Ceyhan, M., Christensen, H., Climent, Y., De Wals, P., Dinleyici, E. C., et al. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1557520 · Cited by 191
Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia
Marshall, H. S., McMillan, M., Koehler, A. P., Lawrence, A., Sullivan, T. R., MacLennan, J. M., Maiden, M. C. J., Ladhani, S. N., Ramsay, M. E., Trotter, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1900236 · Cited by 189
Self-citationReview of Meningococcal Group B Vaccines
Granoff, D. M. (2010) · Clinical Infectious Diseases · doi:10.1086/648966 · Cited by 189
The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014
Whittaker, R., Dias, J. G., Ramliden, M., Ködmön, C., Economopoulou, A., Beer, N., Pastore Celentano, L., Kanitz, E., Richter, L., Mattheus, W., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.007 · Cited by 179
“Meningococcal conjugate vaccines may possibly induce capsular replacement, but there has been no evidence of this following MCC vaccine introduction [9,30].”
BackgroundMeningococcal C conjugate vaccine: the experience in England and Wales
Campbell, H., Borrow, R., Salisbury, D., & Miller, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.067 · Cited by 168
Meningococcal disease: changes in epidemiology and prevention
Stephens, D. S., Chang, Q., & Tzeng (2012) · Clinical Epidemiology · doi:10.2147/clep.s28410 · Cited by 167
Granoff, D. M., Welsch, J. A., & Ram, S. (2009) · Infection and Immunity · doi:10.1128/iai.01191-08 · Cited by 161
Metabolic Glycoengineering with N‐Acyl Side Chain Modified Mannosamines
Wratil, P. R., Horstkorte, R., & Reutter, W. G. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601123 · Cited by 161
Novak, R. T., Kambou, J. L., Diomandé, F. V., Tarbangdo, T. F., Ouédraogo-Traoré, R., Sangaré, L., Lingani, C., Martin, S. W., Hatcher, C., Mayer, L. W., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70168-8 · Cited by 158
Epidemiological Profile of Meningococcal Disease in the United States
Harrison, L. H. (2010) · Clinical Infectious Diseases · doi:10.1086/648963 · Cited by 150
A dual role of extracellular DNA during biofilm formation of Neisseria meningitidis
Lappann, M., Claus, H., Van Alen, T., Harmsen, M., Elias, J., Molin, S., & Vogel, U. (2010) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07054.x · Cited by 149
Bexsero: A multicomponent vaccine for prevention of meningococcal disease
GORRINGE, A. R., & Pajón, R. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.18500 · Cited by 148
Caugant, D. A. (2008) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2008.04.002 · Cited by 145
The epidemiology of meningococcal disease and the impact of vaccines
Khatami, A., & Pollard, A. J. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.3 · Cited by 142
Bröker, M., Costantino, P., DeTora, L. M., McIntosh, E. D. G., & Rappuoli, R. (2011) · Biologicals · doi:10.1016/j.biologicals.2011.05.004 · Cited by 141
Harrison, L. H., Pelton, S. I., Wilder‐Smith, A., Holst, J., Sáfadi, M. A. P., Vázquez, J. A., Taha, M., LaForce, F. M., von Gottberg, A., Borrow, R., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.02.058 · Cited by 139
Emergence of Epidemic Neisseria meningitidis Serogroup X Meningitis in Togo and Burkina Faso
Delrieu, I., Yaro, S., Tamekloe, T. A., Njanpop‐Lafourcade, B., Tall, H., Jaillard, P., Ouedraogo, M. S., Badziklou, K., Sanou, O., Drabo, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019513 · Cited by 135
Vaccination and herd immunity: what more do we know?
Rashid, H., Khandaker, G., & Booy, R. (2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328352f727 · Cited by 133
Deasy, A. M., Guccione, E., Dale, A. P., Andrews, N., Evans, C. M., Bennett, J. S., Bratcher, H. B., Maiden, M. C. J., Gorringe, A. R., & Read, R. C. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ098 · Cited by 125
“conferred by reduced carriage and transmission [3], akin”
BackgroundSelf-citationLadhani, S. N., Flood, J. S., Ramsay, M. E., Campbell, H., Gray, S. J., Kaczmarski, E. B., Mallard, R. H., Guiver, M., Newbold, L. S., & Borrow, R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.03.011 · Cited by 124
Self-citationOverview of the development and current use of CRM197 conjugate vaccines for pediatric use
Shinefield, H. R. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.04.072 · Cited by 123
Crum‐Cianflone, N. F., & Sullivan, E. L. (2016) · Infectious Diseases and Therapy · doi:10.1007/s40121-016-0107-0 · Cited by 120
Jackson, L. A., Baxter, R. P., Reisinger, K. S., Karsten, A., Shah, J., Bedell, L., Dull, P. M., & the V59P13 Study Group (2009) · Clinical Infectious Diseases · doi:10.1086/599117 · Cited by 117
Dretler, A. W., Rouphael, N., & Stephens, D. S. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1451810 · Cited by 114
Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles
Bai, X., Findlow, J., & Borrow, R. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.585965 · Cited by 106
Population genomics: diversity and virulence in the Neisseria
Maiden, M. C. J. (2008) · Current Opinion in Microbiology · doi:10.1016/j.mib.2008.09.002 · Cited by 105
Self-citationMustapha, M. M., Marsh, J. W., & Harrison, L. H. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.014 · Cited by 103
Vaccines for Gonorrhea: Can We Rise to the Challenge?
Zhu, W., Chen, C.-J., Thomas, C., Anderson, J. E., Jerse, A. E., & Sparling, P. F. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00124 · Cited by 103
Evans, C. M., Pratt, C. B., Matheson, M., Vaughan, T. E., Findlow, J., Borrow, R., GORRINGE, A. R., & Read, R. C. (2010) · Clinical Infectious Diseases · doi:10.1093/cid/ciq065 · Cited by 101
Lucidarme, J., Tan, L., Exley, R. M., Findlow, J., Borrow, R., & Tang, C. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00055-11 · Cited by 94
Bröker, M., Dull, P. M., Rappuoli, R., & Costantino, P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.07.036 · Cited by 93
An update on vaccination against group B streptococcus
Heath, P. T. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.61 · Cited by 91
Granoff, D. M. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.066 · Cited by 90
Santolaya, M. E., O’Ryan, M., Valenzuela, M. T., Prado, V., Vergara, R., Muñoz, A., Toneatto, D., Graña, G., Wang, H., & Dull, P. M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25505 · Cited by 89
Perrett, K. P., Winter, A. P., Kibwana, E., Jin, C., John, T. M., Yu, L., Borrow, R., Curtis, N. C., & Pollard, A. J. (2010) · Clinical Infectious Diseases · doi:10.1086/652765 · Cited by 89
Effectiveness of meningococcal serogroup C vaccine programmes
Borrow, R., Abad, R., Trotter, C., van der Klis, F. R. M., & Vazquez, J. A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.083 · Cited by 88
Variation of the factor H-binding protein of Neisseria meningitidis
Brehony, C., Wilson, D. J., & Maiden, M. C. J. (2009) · Microbiology · doi:10.1099/mic.0.027995-0 · Cited by 88
Self-citationAnnual report of the Australian Meningococcal Surveillance Programme 1996
Australian Meningococcal Surveillance Programme, & TAPSALL, J. W. (1997) · Communicable Diseases Intelligence · doi:10.33321/cdi.1997.21.44 · Cited by 87
A Decade of Herd Protection After Introduction of Meningococcal Serogroup C Conjugate Vaccination
Bijlsma, M. W., Brouwer, M. C., Spanjaard, L., van de Beek, D., & van der Ende, A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu601 · Cited by 86
History of meningococcal vaccines and their serological correlates of protection
Vipond, C., Care, R. S., & Feavers, I. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.060 · Cited by 83
Routinely vaccinating adolescents against meningococcus: targeting transmission & disease
Vetter, V., Baxter, R. P., Denizer, G., Sáfadi, M. A. P., Silfverdal, S., Vyse, A., & Borrow, R. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1130628 · Cited by 83
Gabutti, G., Stefanati, A., & Kuhdari, P. (2015) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2015.56.3.478 · Cited by 82
Jackson, L. A., Jacobson, R. M., Reisinger, K. S., Anemona, A., Danzig, L. E., & Dull, P. M. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31818a0237 · Cited by 82
Carr, J. P. J., MacLennan, J. M., Plested, E. L., Bratcher, H. B., Harrison, O. B., Aley, P. K., Bray, J. E., Camara, S., Rodrigues, C. M. C., Davis, K., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.07.004 · Cited by 81
Self-citationInvasive Meningococcal Capsular Group Y Disease, England and Wales, 2007–2009
Ladhani, S. N., Lucidarme, J., Newbold, L. S., Gray, S. J., Carr, A. D., Findlow, J., Ramsay, M. E., Kaczmarski, E. B., & Borrow, R. (2012) · Emerging infectious diseases · doi:10.3201/eid1801.110901 · Cited by 79
Self-citationJolley, K. A., Hill, D. M. C., Bratcher, H. B., Harrison, O. B., Feavers, I. M., Parkhill, J., & Maiden, M. C. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01312-12 · Cited by 78
Self-citationJeppesen, C. A., Snape, M. D., Robinson, H., Gossger, N., John, T. M., Voysey, M., Ladhani, S. N., Okike, I. O., Oeser, C., Kent, A., et al. (2015) · Journal of Infection · doi:10.1016/j.jinf.2015.02.006 · Cited by 77
Self-citationGlycoconjugate vaccines: an update
Vella, M., & Pace, D. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.993375 · Cited by 77
Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges
Mustapha, M. M., & Harrison, L. H. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1412020 · Cited by 77
Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature
Balmer, P., Burman, C., Serra, L., & York, L. J. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1454570 · Cited by 77
Cooper, B. W., DeTora, L. M., & Stoddard, J. J. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.147 · Cited by 76
Brehony, C., Rodrigues, C. M. C., Borrow, R., Smith, A. H., Cunney, R., Moxon, E. R., & Maiden, M. C. J. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.08.015 · Cited by 74
Self-citationKristiansen, P. A., Ba, A. K., Ouédraogo, A., Sanou, I., Ouédraogo, R., Sangaré, L., Diomandé, F. V. K., Kandolo, D., Saga, I. M., Misegades, L. K., et al. (2014) · BMC Infectious Diseases · doi:10.1186/s12879-014-0663-4 · Cited by 73
Global practices of meningococcal vaccine use and impact on invasive disease
Ali, A., Jafri, R. Z., Messonnier, N., Tevi-Benissan, C., Durrheim, D., Eskola, J., Fermon, F., Klugman, K. P., Ramsay, M., Sow, S., et al. (2014) · Pathogens and Global Health · doi:10.1179/2047773214y.0000000126 · Cited by 72
Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa
Mohammed, I., Iliyasu, G., & Habib, A. G. (2017) · Pathogens and Global Health · doi:10.1080/20477724.2016.1274068 · Cited by 72
A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty
Andrews, S. M., & Pollard, A. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70341-4 · Cited by 71
Seroprevalence of Antibodies against Serogroup C Meningococci in England in the Postvaccination Era
Trotter, C. L., Borrow, R., Findlow, J., Holland, A., Frankland, S., Andrews, N. J., & Miller, E. (2008) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00279-08 · Cited by 70
Self-citationSáfadi, M. A. P., O’Ryan, M., Valenzuela, M. T., Brandileone, M. C. C., Gorla, M. C., de Lemos, A. P. S., Moreno, G., Vázquez, J. A., López, E. L., Taha, M., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.055 · Cited by 70
Stoof, S. P., Rodenburg, G. D., Knol, M. J., Rümke, L. W., Man-Bovenkerk, S., Berbers, G. A. M., Spanjaard, L., ENDE, A. V. D., & Sanders, E. A. M. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ506 · Cited by 70
Meningococcal glycoconjugate vaccines
Gasparini, R., & Panatto, D. (2011) · Human Vaccines · doi:10.4161/hv.7.2.13717 · Cited by 68
Micoli, F., Romano, M. R., Tontini, M., Cappelletti, E., Gavini, M., Proietti, D., Rondini, S., Swennen, E., Santini, L., Filippini, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314476110 · Cited by 68
Pharyngeal carriage of Neisseria species in the African meningitis belt
Diallo, K., Trotter, C. L., Timbine, Y., Tamboura, B., Sow, S. O., Issaka, B. B., Dano, I. D., Collard, J., Dieng, M., Diallo, A., et al. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.03.010 · Cited by 68
Self-citationSáfadi, M. A. P., Ayala, S. E. G., Jäkel, A., Wieffer, H., Moreno, C. S., & Vyse, A. (2012) · Epidemiology and Infection · doi:10.1017/s0950268812001689 · Cited by 67
Invasive meningococcal disease and travel
Memish, Z. A., Goubeaud, A., Bröker, M., Malerczyk, C., & Shibl, A. M. (2010) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2010.09.008 · Cited by 66
Bacterial meningitis in Finland, 1995–2014: a population-based observational study
Polkowska, A., Toropainen, M., Ollgren, J. P., Lyytikäinen, O., & Nuorti, J. P. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015080 · Cited by 65
Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006–2015
du Châtelet, I. P., Deghmane, A., Antona, D., Hong, E., Fonteneau, L., Taha, M., & Lévy-Bruhl, D. (2017) · Journal of Infection · doi:10.1016/j.jinf.2017.02.011 · Cited by 64
Li, J., Shao, Z., Liu, G., Bai, X., Borrow, R., Chen, M., Guo, Q., Han, Y., Li, Y., Taha, M., et al. (2018) · Journal of Infection · doi:10.1016/j.jinf.2018.01.007 · Cited by 63
Invasive meningococcal disease in patients with complement deficiencies: a case series (2008–2017)
Ladhani, S. N., Campbell, H., Lucidarme, J., Gray, S. J., Parikh, S. R., Willerton, L., Clark, S. A., Lekshmi, A., Walker, A., Patel, S. R., et al. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4146-5 · Cited by 63
Self-citationNeisseria meningitidisB vaccines
Panatto, D., Amicizia, D., Lai, P. L., & Gasparini, R. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.103 · Cited by 62
Carriage ofNeisseria meningitidisin Europe: a review of studies undertaken in the region
Soriano‐Gabarró, M., Wolter, J. M., Hogea, C. S., & Vyse, A. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.89 · Cited by 61
Neisseria meningitidis: epidemiology, treatment and prevention in adolescents
Brigham, K. S., & Sandora, T. J. (2009) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32832c9668 · Cited by 62
Pouwels, K. B., Hak, E., ENDE, A. V. D., Christensen, H., van den Dobbelsteen, G. P. J. M., & Postma, M. J. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23888 · Cited by 61
Early Estimate of the Effectiveness of Quadrivalent Meningococcal Conjugate Vaccine
MacNeil, J. R., Cohn, A. C., Zell, E. R., Schmink, S. E., Miller, E. R., Clark, T. A., & Messonnier, N. E. (2011) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31820a8b3c · Cited by 61
Carriage of Meningococci by University Students, United Kingdom
Ala'Aldeen, D. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1709.101762 · Cited by 58
Self-citationCeyhan, M., Çelik, M., Demir, E., Gürbüz, V., Aycan, A. E., & Ünal, S. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00314-12 · Cited by 58
Sáfadi, M. A. P., Carvalhanas, T. R. M. P., de Lemos, A. P. S., Gorla, M. C., Salgado, M. M., Fukasawa, L. O., Gonçalves, M. G., Higa, F. T., Brandileone, M. C. D. C., Sacchi, C. T., et al. (2014) · Emerging infectious diseases · doi:10.3201/eid2005.130948 · Cited by 57
An Overview of Neisseria meningitidis
Hollingshead, S., & Tang, C. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9202-7_1 · Cited by 59
Obolski, U., Lourenço, J., Thompson, C., Thompson, R. N., Gori, A., & Gupta, S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718712115 · Cited by 58
Pace, D. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.725718 · Cited by 57
The changing epidemiology of meningococcal disease in North America 1945–2010
Baccarini, C. I., Ternouth, A., Wieffer, H., & Vyse, A. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22302 · Cited by 56
Martinón‐Torres, F., Taha, M., Knuf, M., Abbing‐Karahagopian, V., Pellegrini, M., Bekkat-Berkani, R., & Abitbol, V. (2021) · Pathogens and Global Health · doi:10.1080/20477724.2021.1972663 · Cited by 55
Mechanisms of meningococcal colonisation
Trivedi, K., Tang, C. M., & Exley, R. M. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.06.006 · Cited by 53
Metadata
- Authors
- Maiden, M. C. J., Ibarz-Pavón, A. B., Urwin, R., Gray, S. J., Andrews, N. J., Clarke, S. C., Walker, A. M., Evans, M. R., Kroll, J. S., Neal, K. R., Ala'Aldeen, D. A. A., Crook, D. W., Cann, K., Harrison, S., Cunningham, R., Baxter, D., Kaczmarski, E., MacLennan, J., Cameron, J. C., & Stuart, J. M.
- Affiliations
- John Radcliffe Hospital (GB)
- Health Protection Agency (GB)
- Health Protection Agency Centre for Infections, London
- University of Southampton (GB)
- Bangor University (GB)
- National Public Health Service for Wales, Unit 1, Parc Nantgarw, Cardiff
- Imperial College London (GB)
- University of Nottingham (GB)
- Division of Microbiology, School of Molecular Medical Sciences, Institute of Infection Immunity and Inflammation University of Nottingham
- South West Peninsula Health Protection Unit, Lescaze Offices, Dartington, Devon
- Derriford Hospital (GB)
- University of Manchester (GB)
- Manchester Royal Infirmary (GB)
- Health Protection Scotland (GB)
- Corresponding author
- Maiden, Martin C J
- ORCID
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-01
- Volume
- 197
- Issue
- 5
- Pages
- 737-743
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC6767871
- OpenAlex
- W2171028861
- Cited by
- 442
- References
- 41
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 9 · 2023: 16 · 2022: 10 · 2021: 21 · 2020: 18 · 2019: 21 · 2018: 29 · 2017: 32 · 2016: 24 · 2015: 40 · 2014: 22 · 2013: 28 · 2012: 45
- FWCI
- 35.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Funders
- Wellcome Trust
- Scottish Executive Health Department
- Meningitis Trust
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Life Sciences › Immunology and Microbiology › Microbiology › Microbial infections and disease research
- Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
- Keywords
- meningococcal serogroup C, conjugate vaccines, asymptomatic carriage, herd immunity, serogroup replacement, capsule expression, vaccine efficacy, young children, United Kingdom
- MeSH terms
- Adolescent, Adult, Carrier State, Cross-Sectional Studies, United Kingdom, Humans, Meningococcal Infections, Neisseria meningitidis, Serotyping, Meningococcal Vaccines, Immunity, Herd, Mass Vaccination, Neisseria meningitidis, Serogroup C
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.